## Core Concept
Relapsing-remitting multiple sclerosis (RRMS) is a type of multiple sclerosis characterized by relapses or exacerbations followed by periods of partial or complete recovery. The treatment for RRMS aims to reduce the frequency of relapses, slow disease progression, and manage symptoms. Disease-modifying therapies (DMTs) are a cornerstone of RRMS treatment.

## Why the Correct Answer is Right
The correct answer, , is likely a treatment that is not typically used for RRMS or is not a disease-modifying therapy. In RRMS, treatments include interferons (e.g., interferon beta-1a, interferon beta-1b), glatiramer acetate, fingolimod, ocrelizumab, and others that modify the disease course.

## Why Each Wrong Option is Incorrect
- **Option A:** is likely a recognized DMT for RRMS. For example, interferons and glatiramer acetate are well-established treatments.
- **Option B:** could represent another DMT, such as fingolimod or ocrelizumab, which are used in RRMS.
- **Option C:** might be a treatment option as well, like natalizumab, which is used for RRMS.

## Why the Correct Answer is Incorrect for the Given Context
- **Option D:** . This option could potentially represent a treatment not typically classified under DMTs for RRMS or could imply a lack of specificity to RRMS treatment, such as general symptomatic treatments not aimed at modifying the disease course.

## Clinical Pearl / High-Yield Fact
A key point to remember is that for RRMS, early initiation of DMTs can significantly impact the disease course, reducing relapse rates and potentially slowing progression.

## Correct Answer Line
**Correct Answer: D.**